Literature DB >> 96277

Pseudomonas colonization in cystic fibrosis. A study of 160 patients.

L L Kulczycki, T M Murphy, J A Bellanti.   

Abstract

We investigated the role of Pseudomonas aeruginosa colonization in the respiratory tracts of cystic fibrosis (CF) patients to relate the effect of this colonization to progression of bronchial airway pathologic conditions and to the patients' clinical progress, and to identify predisposing factors to persistence of P aeruginosa colonization and bronchial tree damage. Half of 160 CF patients studied had persistent P aeruginosa respiratory tract colonization; the other half had none. Pseudomonas aeruginosa seems to have an exclusive propensity for the respiratory tract and may appear at any age. Treatment with antibiotics, including aminoglycosides, failed to eradicate P aeruginosa. The continuous use of antibiotics seemed to contribute to the persistence of P aeruginosa and the appearance of mucoid strains of P aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 96277

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  37 in total

1.  Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways.

Authors:  K B Adler; D D Hendley; G S Davis
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

2.  Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis.

Authors:  S W Hla; K P Hui; W C Tan; B Ho
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats.

Authors:  O F Join-Lambert; M Michéa-Hamzehpour; T Köhler; F Chau; F Faurisson; S Dautrey; C Vissuzaine; C Carbon; J Pechère
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  A Penketh; M E Hodson; H Gaya; J C Batten
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

5.  Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. British Thoracic Society Research Committee.

Authors: 
Journal:  Thorax       Date:  1985-05       Impact factor: 9.139

6.  Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.

Authors:  M R Shreve; S Butler; H J Kaplowitz; H R Rabin; D Stokes; M Light; W E Regelmann
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

7.  Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.

Authors:  J L Gaillard; P Cahen; C Delacourt; C Silly; M Le Bourgeois; C Coustère; J de Blic; G Lenoir; P Scheinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

8.  Involvement of the alginate algT gene and integration host factor in the regulation of the Pseudomonas aeruginosa algB gene.

Authors:  D J Wozniak; D E Ohman
Journal:  J Bacteriol       Date:  1993-07       Impact factor: 3.490

9.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 10.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.